KBC Group
PGNX

KBC Group’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

KBC Group’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-12,732
Closed -$48K – 1341
2020
Q1 		$48K Hold
12,732
– – ﹤0.01% 1204
2019
Q4 		$65K Buy
12,732
+12,707
+50,828% +$67.2K ﹤0.01% 1399
2019
Q3 		$0 Sell
25
-22,147
-100% -$110K ﹤0.01% 1515
2019
Q2 		$137K Hold
22,172
– – ﹤0.01% 1277
2019
Q1 		$103K Buy
22,172
+2,700
+14% +$12.2K ﹤0.01% 1276
2018
Q4 		$82K Sell
19,472
-328,731
-94% -$1.67M ﹤0.01% 1190
2018
Q3 		$2.18M Buy
348,203
+129,580
+59% +$995K 0.02% 646
2018
Q2 		$1.76M Hold
218,623
– – 0.02% 636
2018
Q1 		$1.63M Buy
218,623
+1,051
+0.5% +$6.99K 0.02% 622
2017
Q4 		$1.29M Sell
217,572
-17,205
-7% -$105K 0.01% 728
2017
Q3 		$1.73M Buy
234,777
+21,791
+10% +$138K 0.02% 644
2017
Q2 		$1.45M Buy
212,986
+96,082
+82% +$709K 0.01% 670
2017
Q1 		$1.1M Buy
+116,904
New +$1.17M 0.01% 840

Other funds holding PGNX

ECM
Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $49.2B AUM 29.3% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

KBC Group's PGNX Position: Q2 2020 in Review

KBC Group sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 12,732 shares — an estimated $48K sold.

KBC Group first reported a position in PGNX in Q1 2017 and held it in 13 quarters. The position peaked at $2.18M in Q3 2018. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • KBC Group reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • KBC Group sold 12,732 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $48K.
  • KBC Group first reported a position in Progenics Pharmaceuticals Inc in Q1 2017 and held it in 13 quarters.
  • KBC Group's Progenics Pharmaceuticals Inc position peaked at $2.18M in Q3 2018.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on KBC Group's 13F filing for Q2 2020, filed 10 Aug 2020.